Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ARADIGM CORPARDM · Entity 155143 | Director | June 29, 2018 | July 03, 2018 |
| Processa Pharmaceuticals, Inc.PCSA · Entity 8210 | Director | June 27, 2023 | July 24, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ARADIGM CORP
Report date June 29, 2018 · Filed July 03, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.45 · Expires 2028-06-29 | Direct | 97,323 |
Reported balance
After 2018-06-29 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-06-29 · Grant · Acquired 97,323 · Balance 97,323 F1: The shares underlying the option shall vest and become exercisable in four equal quarterly installments over one year beginning on June 29, 2018, subject to such individual continuing to be a Participant (as defined in the 2015 Equity Incentive Plan) on the relevant vesting dates. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying the option shall vest and become exercisable in four equal quarterly installments over one year beginning on June 29, 2018, subject to such individual continuing to be a Participant (as defined in the 2015 Equity Incentive Plan) on the relevant vesting dates.
Processa Pharmaceuticals, Inc.
Report date June 27, 2023 · Filed July 24, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Thompson Family Trus | 123,849 |
Reported balance
After 2023-06-27 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2023-06-27 · Exercise / conversion · Acquired 23,636 · Balance 123,849 F1: Vesting of time-based restricted shares. |
| Restricted StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2023-06-27 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-06-27 · Exercise / conversion · Disposed 23,636 · Balance 0 F1: Vesting of time-based restricted shares. |
| Restricted StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 101,365 |
Reported balance
After 2023-06-27 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-06-27 · Grant · Acquired 101,365 · Balance 101,365 F2: The restricted stock vests on the earliest of one year from date of grant or the next annual meeting of stockholders. |
| Common StockSEC Table I · non-derivative | Direct | 16,693 |
Reported balance
Holding disclosure · report date 2023-06-27 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 16,693 |
Filing footnotes · ownership attribution and instrument terms
F1: Vesting of time-based restricted shares.
F2: The restricted stock vests on the earliest of one year from date of grant or the next annual meeting of stockholders.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 27, 2023 Filed Jul 24, 2023 18:33 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock · Derivative | 101,365 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000897069-23-001002 · form4.xml · derivative · entry 4 THOMPSON VIRGIL · CIK 0001218821 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,365 Underlying: Common Stock · 101,365 shares Expires not disclosed F2 · derivative.exercise_date: The restricted stock vests on the earliest of one year from date of grant or the next annual meeting of stockholders. F2 · derivative.expiration_date: The restricted stock vests on the earliest of one year from date of grant or the next annual meeting of stockholders. Read SEC document |
| June 27, 2023 Filed Jul 24, 2023 18:33 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | Exercise / conversionRestricted Stock · Derivative | 23,636 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000897069-23-001002 · form4.xml · derivative · entry 3 THOMPSON VIRGIL · CIK 0001218821 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 23,636 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Vesting of time-based restricted shares. F1 · derivative.expiration_date: Vesting of time-based restricted shares. Read SEC document |
| June 27, 2023 Filed Jul 24, 2023 18:33 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | Exercise / conversionCommon Stock | 23,636 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000897069-23-001002 · form4.xml · nonDerivative · entry 1 THOMPSON VIRGIL · CIK 0001218821 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Thompson Family Trus Disclosed balance after: 123,849 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Vesting of time-based restricted shares. Read SEC document |
| January 01, 2023 Filed Jan 4, 2023 17:36 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock · Derivative | 30,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-23-000317 · doc1.xml · derivative · entry 3 THOMPSON VIRGIL · CIK 0001218821 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires not disclosed F2 · derivative.exercise_date: The Restricted Stock vests on the earliest of one year from date of grant or the next annual meeting of stockholders. F2 · derivative.expiration_date: The Restricted Stock vests on the earliest of one year from date of grant or the next annual meeting of stockholders. Read SEC document |
| December 31, 2022 Filed Jan 4, 2023 17:36 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | Exercise / conversionCommon Stock | 18,208 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-23-000317 · doc1.xml · nonDerivative · entry 2 THOMPSON VIRGIL · CIK 0001218821 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Thompson Family Trust Disclosed balance after: 100,213 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Vesting of time-based restricted shares. Read SEC document |
| August 05, 2022 Filed Aug 9, 2022 16:20 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | Exercise / conversionCommon Stock | 1,169 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-22-015300 · doc1.xml · nonDerivative · entry 1 THOMPSON VIRGIL · CIK 0001218821 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,693 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Vesting of time-based restricted shares. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 17:55 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantCommon Stock | 4,393 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-22-008008 · doc1.xml · nonDerivative · entry 1 THOMPSON VIRGIL · CIK 0001218821 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,693 F1 · price: Vesting of time-based restricted shares. Read SEC document |
| January 01, 2022 Filed Apr 19, 2022 21:17 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock · Derivative | 18,208 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-008683 · doc1.xml · derivative · entry 1 THOMPSON VIRGIL · CIK 0001218821 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,377 Underlying: Common Stock · 18,208 shares Expires not disclosed F1 · derivative.exercise_date: Restricted stock units vest 100% on December 31, 2022. F1 · derivative.expiration_date: Restricted stock units vest 100% on December 31, 2022. Read SEC document |
| August 05, 2021 Filed Aug 9, 2021 16:35 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantCommon Stock | 1,169 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-21-014745 · doc1.xml · nonDerivative · entry 1 THOMPSON VIRGIL · CIK 0001218821 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,300 F1 · price: Vesting of time-based restricted shares. Read SEC document |
| June 29, 2018 Filed Jul 3, 2018 17:25 UTC | ARADIGM CORP ARDM · Entity 155143 | GrantStock Option (Right to Buy) · Derivative | 97,323 | $0.00 Strike: $1.45 | $0.00 |
DisclosureSEC source: 0001123292-18-000850 · edgar.xml · derivative · entry 1 THOMPSON VIRGIL · CIK 0001218821 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,323 Underlying: Common Stock · 97,323 shares Expires 2028-06-29 F1 · derivative.exercise_date: The shares underlying the option shall vest and become exercisable in four equal quarterly installments over one year beginning on June 29, 2018, subject to such individual continuing to be a Participant (as defined in the 2015 Equity Incentive Plan) on the relevant vesting dates. Read SEC document |
| June 01, 2017 Filed Jun 5, 2017 17:52 UTC | ARADIGM CORP ARDM · Entity 155143 | GrantStock Option (Right to Buy) · Derivative | 110,485 | $0.00 Strike: $1.39 | $0.00 |
DisclosureSEC source: 0001123292-17-001081 · edgar.xml · derivative · entry 1 THOMPSON VIRGIL · CIK 0001218821 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,485 Underlying: Common Stock · 110,485 shares Expires 2027-06-01 F1 · derivative.exercise_date: The shares underlying the option shall vest and become exercisable in four equal quarterly installments over one year beginning on June 1, 2017, subject to such individual continuing to be a Participant (as defined in the 2015 Equity Incentive Plan) on the relevant vesting dates. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.